FeesSafety
Pluang+

Centrifuge simplifies onchain pool creation for fund managers with a new three-step process.

Protocol Fundamentals
31 Aug 2026
Crypto Economy
View Source
Bullish
Centrifuge simplifies onchain pool creation for fund managers with a new three-step process.

Centrifuge has launched an updated app feature that streamlines the creation of onchain pools for fund managers. The new process allows managers to structure and launch pools in just three steps, giving them greater control and efficiency. This update aims to make managing decentralized finance (DeFi) investments easier and faster, potentially attracting more fund managers to use the platform.

More News

Anthropic's revenue jumps to $16.3B in H1 2026, up from $1.1B last year

Anthropic's revenue jumps to $16.3B in H1 2026, up from $1.1B last year

Anthropic reported a massive increase in revenue, reaching $16.3 billion in the first half of 2026 compared to just $1.1 billion in the same period last year. This surge highlights rapid growth and strong demand for its products or services. The dram...

Market News
Bullish
1 hour ago
Early Ethereum investors sold 4,000 ETH amid largest net outflow in 4 months, signaling potential market shifts.

Early Ethereum investors sold 4,000 ETH amid largest net outflow in 4 months, signaling potential market shifts.

Early Ethereum investors sold a total of 4,000 ETH from two wallets, with one ICO participant selling 1,000 ETH and another holder offloading 3,000 ETH worth $7.23 million. This activity coincides with Santiment's report of the largest daily net ETH ...

Market News
Bearish
4 hours ago
Immatics shows promising anti-tumor results with IMA402 and IMA203CD8 therapies at ESMO 2026.

Immatics shows promising anti-tumor results with IMA402 and IMA203CD8 therapies at ESMO 2026.

Immatics presented encouraging clinical data for its IMA402 PRAME bispecific and IMA203CD8 PRAME cell therapies at the 2026 ESMO Annual Meeting. IMA402 showed a 32% confirmed objective response rate (cORR) in advanced melanoma patients with high PRAM...

Market News
Bullish
4 hours ago
Sofetabart mipitecan plus bevacizumab shows 79% response rate in platinum-sensitive ovarian cancer Phase 1 trial

Sofetabart mipitecan plus bevacizumab shows 79% response rate in platinum-sensitive ovarian cancer Phase 1 trial

Eli Lilly's investigational drug sofetabart mipitecan (Sofe-M), combined with bevacizumab, achieved a 79% confirmed objective response rate and 100% disease control rate in a Phase 1 study involving platinum-sensitive ovarian cancer patients. The tre...

Company Fundamentals
Bullish
4 hours ago
ZW191 shows strong anti-tumor effects in tough ovarian cancer cases, advancing clinical development.

ZW191 shows strong anti-tumor effects in tough ovarian cancer cases, advancing clinical development.

Zymeworks presented new Phase 1 data for ZW191, an antibody-drug conjugate targeting folate receptor alpha, showing a 64.5% confirmed response rate at the 6.4 mg/kg dose in heavily pretreated patients with platinum-resistant ovarian cancer. The treat...

Company Fundamentals
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App